

Glucagon-like Peptide-1 (GLP-1) Receptor agonist Adjudication Guideline

Rule Category:
Pharmaceutical

Ref: No:
2021-PH-09

Version Control:
Version No. V2.1

Effective Date:
15/01/2022

Last Update:
02/11/2023

Approved by:
Daman

Responsible:
Medical Standards
& Research

**Related Adjudication
Guidelines:** NA

Table of Contents

1.	Abstract	3
1.1	For Members.....	3
1.2	For Healthcare Professionals.....	2
2.	Scope	3
3.	Adjudication Policy.....	3
3.1	Eligibility / Coverage Criteria.....	3
3.2	Requirements for Coverage	4
3.3	Non-Coverage.....	4
3.4	Payment and Coding Rules	4
4.	Denial codes	4
5.	Appendices	4
5.1	References	4
5.2	Revision History	5

1. Abstract

1.1 For Members

Glucagon-like peptide-1 (GLP-1) receptor agonist are medicines used to treat type 2 diabetes. They mimic the action of a hormone called GLP-1.

1.2 For Healthcare Professionals

Glucagon-like peptide-1 (GLP-1) receptor agonist is indicated for the treatment of type 2 diabetes mellitus. They are prescribed in adjunct to lifestyle modifications (such as diet and exercise).

2. Scope

The scope of this adjudication rule highlights the medical indications and coverage requirements of GLP-1 receptor agonists for type 2 diabetes for all health insurance plans administered by Daman as per policy terms and conditions.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

Glucagon-like peptide-1 (GLP-1) receptor agonist is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Coverage Criteria for All GLP-1 Receptor agonists (any one of the following):

1. Type 2 diabetes with no history of any previous diabetic medication or not reaching the maximum tolerable dose of previous diabetic medication
 - HBA1c $\geq$ 6.5 in addition to the presence of comorbidities or contraindication to oral diabetic medication
2. Known case of type 2 diabetes with history of maximum indicated diabetic medication dosage
 - Poor glycemic control (HBA1C $\geq$ 6.5)
3. Known case of type 2 diabetes requiring a therapy shift from other GLP-1 RA:
 - (HBA1C $\geq$ 6.5)

Contraindicated in patients with:

- Multiple endocrine neoplasia (MEN) syndrome type 2
- Personal or family history of medullar thyroid cancer
- Pancreatitis
- Type 1 diabetes mellitus or diabetic ketoacidosis
- Pregnancy and breastfeeding.
- Age < 18 years of age

3.2 Requirements for Coverage

- Failure to submit, upon request or when requesting a clinical history, an indication and the need for testing will result in the rejection of the claim.
- Below is the list of eligible clinician specialty

Eligible clinician specialties
Internal Medicine
Endocrinology
Family Medicine
Cardiologist

3.3 Non-Coverage

Generic Name	Package Name
Visitor plan	Not covered
Basic plan	Not covered
Enhanced	Covered
Thiqa	Covered

3.4 Payment and Coding Rules

- Please apply regulator payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

4. Denial Codes

DOH denial codes with description are elaborated for reference. These are specialized codes directed by DOH, that explains the reason of rejection of the service by DAMAN to the providers.

Code	Code Description
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnosis/activities.
MNEC-005	Services/supply may be appropriate but too frequent.
AUTH-001	Prior approval is required and was not obtained.
CLAI-016	Incorrect billing regime.

5. Appendices

5.1 References

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf
3. <https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon>
4. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
5. <https://www.medicines.org.uk/emc/medicine/19257#gref>
6. <https://www.medicines.org.uk/emc/product/2967#gref>
7. <https://www.medscape.com/answers/117853-6512/are-glucagonlike-peptide-1-glp-1-agonists-beneficial-in-the-treatment-of-type-2-diabetes-mellitus-dm>
8. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
9. Tirzepatide 10mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)

5.2 Revision History

Date	Change(s)
24/05/2023	Release of V1.0
08/09/2023	Release of V2.0-Tirzepatide criteria addition
27/09/2023	Update of Coverage Criteria
11/02/2023	Update of Criteria

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by The National Insurance Company – Daman (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.